InvestorsHub Logo
Followers 18
Posts 777
Boards Moderated 0
Alias Born 02/17/2006

Re: None

Tuesday, 03/22/2022 11:00:14 AM

Tuesday, March 22, 2022 11:00:14 AM

Post# of 834
3/22 Oragenics Initiates a Pivotal IND-Enabling Toxicology Study on its Intranasal COVID-19 Vaccine Candidate, NT-CoV2-1

"“We are thrilled to have begun this pivotal study with Frontage, a premier drug development contract research organization, and are thankful to the acceleration Frontage has offered our important IND-enabling study. We believe the results from this rabbit toxicology study will support our development strategy for our intranasal COVID-19 vaccine candidate, NT-CoV2-1. The intranasal delivery route is particularly relevant as it may further reduce transmission of the virus and provide a needle-free delivery option. The findings from this preclinical toxicology study will be a part of our Investigational New Drug filing to the U.S. Food and Drug Administration,” said Frederick W. Telling, Ph.D., Executive Chairman of Oragenics."


https://ir.oragenics.com/press-releases/detail/142

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent OGEN News